JPH0368506B2 - - Google Patents

Info

Publication number: JPH0368506B2
Authority: JP; Japan
Prior art keywords: positive electrode; fes; organic solvent; battery; discharge
Prior art date: 1982-03-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP57048873A

Other languages

English (en)

Japanese (ja)

Other versions

JPS58166633A (ja

Inventor

Takahisa Oosaki

Shuji Yamada

Juichi Sato

Tsutomu Takamura

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Toshiba Corp

Original Assignee

Tokyo Shibaura Electric Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-29

Filing date

1982-03-29

Publication date

1991-10-28

1982-03-29 Application filed by Tokyo Shibaura Electric Co Ltd filed Critical Tokyo Shibaura Electric Co Ltd

1982-03-29 Priority to JP57048873A priority Critical patent/JPS58166633A/ja

1983-10-01 Publication of JPS58166633A publication Critical patent/JPS58166633A/ja

1991-10-28 Publication of JPH0368506B2 publication Critical patent/JPH0368506B2/ja

Status Granted legal-status Critical Current

Links

239000003960 organic solvent Substances 0.000 claims description 17
239000000843 powder Substances 0.000 claims description 14
239000011149 active material Substances 0.000 claims description 11
229910000358 iron sulfate Inorganic materials 0.000 claims description 11
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 11
NFMAZVUSKIJEIH-UHFFFAOYSA-N bis(sulfanylidene)iron Chemical compound S=[Fe]=S NFMAZVUSKIJEIH-UHFFFAOYSA-N 0.000 claims description 3
229910000339 iron disulfide Inorganic materials 0.000 claims description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
229910052744 lithium Inorganic materials 0.000 description 6
239000007774 positive electrode material Substances 0.000 description 5
QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
229910015902 Bi 2 O 3 Inorganic materials 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
229910000416 bismuth oxide Inorganic materials 0.000 description 3
TYIXMATWDRGMPF-UHFFFAOYSA-N dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Bi+3].[Bi+3] TYIXMATWDRGMPF-UHFFFAOYSA-N 0.000 description 3
239000003792 electrolyte Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
-1 polytetrafluoroethylene Polymers 0.000 description 3
YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 2
229910001486 lithium perchlorate Inorganic materials 0.000 description 2
229910052748 manganese Inorganic materials 0.000 description 2
239000011572 manganese Substances 0.000 description 2
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
239000004810 polytetrafluoroethylene Substances 0.000 description 2
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
238000007789 sealing Methods 0.000 description 2
229910001923 silver oxide Inorganic materials 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000005751 Copper oxide Substances 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 1
239000006230 acetylene black Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229930188620 butyrolactone Natural products 0.000 description 1
239000004020 conductor Substances 0.000 description 1
229910000431 copper oxide Inorganic materials 0.000 description 1
OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 description 1
AQKDYYAZGHBAPR-UHFFFAOYSA-M copper;copper(1+);sulfanide Chemical compound [SH-].[Cu].[Cu+] AQKDYYAZGHBAPR-UHFFFAOYSA-M 0.000 description 1
WMVRXDZNYVJBAH-UHFFFAOYSA-N dioxoiron Chemical compound O=[Fe]=O WMVRXDZNYVJBAH-UHFFFAOYSA-N 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
238000001035 drying Methods 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
239000010439 graphite Substances 0.000 description 1
GNVXPFBEZCSHQZ-UHFFFAOYSA-N iron(2+);sulfide Chemical compound [S-2].[Fe+2] GNVXPFBEZCSHQZ-UHFFFAOYSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000007773 negative electrode material Substances 0.000 description 1
239000005486 organic electrolyte Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000010248 power generation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1

Classifications

- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
- H01M4/00—Electrodes
- H01M4/02—Electrodes composed of, or comprising, active material
- H01M4/36—Selection of substances as active materials, active masses, active liquids
- H01M4/58—Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy; of polyanionic structures, e.g. phosphates, silicates or borates
- H01M4/581—Chalcogenides or intercalation compounds thereof
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries

Landscapes

Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Electrochemistry (AREA)
General Chemical & Material Sciences (AREA)
Battery Electrode And Active Subsutance (AREA)

JP57048873A 1982-03-29 1982-03-29 有機溶媒電池用正極 Granted JPS58166633A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP57048873A JPS58166633A (ja)	1982-03-29	1982-03-29	有機溶媒電池用正極

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP57048873A JPS58166633A (ja)	1982-03-29	1982-03-29	有機溶媒電池用正極

Publications (2)

Publication Number	Publication Date
JPS58166633A JPS58166633A (ja)	1983-10-01
JPH0368506B2 true JPH0368506B2 (xx)	1991-10-28

Family

ID=12815402

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57048873A Granted JPS58166633A (ja)	1982-03-29	1982-03-29	有機溶媒電池用正極

Country Status (1)

Country	Link
JP (1)	JPS58166633A (xx)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004050683A2 (en)	2002-12-02	2004-06-17	Abgenix, Inc.	Antibodies directed to tumor necrosis factor and uses thereof
WO2005016111A2 (en)	2003-08-08	2005-02-24	Abgenix, Inc.	Antibodies directed to parathyroid hormone (pth) and uses thereof
WO2005092926A2 (en)	2004-03-19	2005-10-06	Amgen Inc.	Reducing the risk of human and anti-human antibodies through v gene manipulation
WO2006055638A2 (en)	2004-11-17	2006-05-26	Abgenix, Inc.	Fully human monoclonal antibodies to il-13
WO2007059082A1 (en)	2005-11-10	2007-05-24	Curagen Corporation	Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
JP2008525960A (ja) *	2004-12-22	2008-07-17	エバレデイバツテリカンパニーインコーポレーテツド	高放電容量のリチウム・バッテリ
WO2009040134A1 (en)	2007-09-26	2009-04-02	U3 Pharma Gmbh	Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
WO2010072740A2 (en)	2008-12-23	2010-07-01	Astrazeneca Ab	TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2011060206A2 (en)	2009-11-13	2011-05-19	U3 Pharma Gmbh	Material and methods for treating or preventing her-3 associated diseases
EP2357202A1 (en)	2006-04-10	2011-08-17	AstraZeneca AB	Targeted binding agents directed to Upar and uses thereof
EP2361933A2 (en)	2005-01-26	2011-08-31	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
EP2404616A2 (en)	2005-12-13	2012-01-11	AstraZeneca AB	Binding proteins specific for insulin-like growth factors and uses thereof
WO2012018404A2 (en)	2010-08-06	2012-02-09	U3 Pharma Gmbh	Use of her3 binding agents in prostate treatment
EP2420514A1 (en)	2006-08-03	2012-02-22	MedImmune Limited	Targeted binding agents directed to PDGFR-alpha and uses thereof
US8283071B2 (en)	2003-11-21	2012-10-09	Eveready Battery Company, Inc.	High discharge capacity lithium battery
WO2012154999A1 (en)	2011-05-10	2012-11-15	Amgen Inc.	Methods of treating or preventing cholesterol related disorders
WO2013075048A1 (en)	2011-11-16	2013-05-23	Amgen Inc.	Methods of treating epidermal growth factor deletion mutant viii related disorders
US8597615B2 (en)	2004-03-19	2013-12-03	Amgen Fremont Inc.	Methods of monitoring a human anti-human antibody response and inhibitors thereof
US9062113B2 (en)	2003-06-27	2015-06-23	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP2927244A1 (en)	2008-09-19	2015-10-07	MedImmune, LLC	Antibodies directed to DLL4 and uses thereof
WO2016016859A1 (en)	2014-07-31	2016-02-04	Amgen Research (Munich) Gmbh	Optimized cross-species specific bispecific single chain antibody constructs
WO2016166360A1 (en)	2015-04-17	2016-10-20	Bayer Pharma Aktiengesellschaft	Bispecific antibody constructs for cdh3 and cd3
EP3196213A2 (en)	2005-12-30	2017-07-26	Daiichi Sankyo Europe GmbH	Antibodies directed to her-3 and uses thereof

1982
- 1982-03-29 JP JP57048873A patent/JPS58166633A/ja active Granted

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004050683A2 (en)	2002-12-02	2004-06-17	Abgenix, Inc.	Antibodies directed to tumor necrosis factor and uses thereof
US9096672B2 (en)	2003-06-27	2015-08-04	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9085624B2 (en)	2003-06-27	2015-07-21	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9073998B2 (en)	2003-06-27	2015-07-07	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9062113B2 (en)	2003-06-27	2015-06-23	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005016111A2 (en)	2003-08-08	2005-02-24	Abgenix, Inc.	Antibodies directed to parathyroid hormone (pth) and uses thereof
US8283071B2 (en)	2003-11-21	2012-10-09	Eveready Battery Company, Inc.	High discharge capacity lithium battery
US8597615B2 (en)	2004-03-19	2013-12-03	Amgen Fremont Inc.	Methods of monitoring a human anti-human antibody response and inhibitors thereof
WO2005092926A2 (en)	2004-03-19	2005-10-06	Amgen Inc.	Reducing the risk of human and anti-human antibodies through v gene manipulation
WO2006055638A2 (en)	2004-11-17	2006-05-26	Abgenix, Inc.	Fully human monoclonal antibodies to il-13
JP2008525960A (ja) *	2004-12-22	2008-07-17	エバレデイバツテリカンパニーインコーポレーテツド	高放電容量のリチウム・バッテリ
EP2361933A2 (en)	2005-01-26	2011-08-31	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
WO2007059082A1 (en)	2005-11-10	2007-05-24	Curagen Corporation	Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP2404616A2 (en)	2005-12-13	2012-01-11	AstraZeneca AB	Binding proteins specific for insulin-like growth factors and uses thereof
US9988462B2 (en)	2005-12-30	2018-06-05	Daiichi Sankyo Europe Gmbh	Material and methods for treating or preventing HER-3 associated diseases
EP3196213A2 (en)	2005-12-30	2017-07-26	Daiichi Sankyo Europe GmbH	Antibodies directed to her-3 and uses thereof
EP2357202A1 (en)	2006-04-10	2011-08-17	AstraZeneca AB	Targeted binding agents directed to Upar and uses thereof
EP2420514A1 (en)	2006-08-03	2012-02-22	MedImmune Limited	Targeted binding agents directed to PDGFR-alpha and uses thereof
EP2420513A1 (en)	2006-08-03	2012-02-22	MedImmune Limited	Targeted binding agents directed to PDGFR-alpha and uses thereof
WO2009040134A1 (en)	2007-09-26	2009-04-02	U3 Pharma Gmbh	Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EP2497783A2 (en)	2007-09-26	2012-09-12	U3 Pharma GmbH	Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EP2927244A1 (en)	2008-09-19	2015-10-07	MedImmune, LLC	Antibodies directed to DLL4 and uses thereof
WO2010072740A2 (en)	2008-12-23	2010-07-01	Astrazeneca Ab	TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
EP2896632A2 (en)	2009-11-13	2015-07-22	U3 Pharma GmbH	Material and methods for treating or preventing HER-3 associated diseases
US9101760B2 (en)	2009-11-13	2015-08-11	U3 Pharma Gmbh	Material and methods for treating or preventing HER-3 associated diseases
US9803025B2 (en)	2009-11-13	2017-10-31	Amgen, Inc.	Material and methods for treating or preventing HER-3 associated diseases
WO2011060206A2 (en)	2009-11-13	2011-05-19	U3 Pharma Gmbh	Material and methods for treating or preventing her-3 associated diseases
WO2012018404A2 (en)	2010-08-06	2012-02-09	U3 Pharma Gmbh	Use of her3 binding agents in prostate treatment
WO2012154999A1 (en)	2011-05-10	2012-11-15	Amgen Inc.	Methods of treating or preventing cholesterol related disorders
WO2013075048A1 (en)	2011-11-16	2013-05-23	Amgen Inc.	Methods of treating epidermal growth factor deletion mutant viii related disorders
WO2016016859A1 (en)	2014-07-31	2016-02-04	Amgen Research (Munich) Gmbh	Optimized cross-species specific bispecific single chain antibody constructs
WO2016166360A1 (en)	2015-04-17	2016-10-20	Bayer Pharma Aktiengesellschaft	Bispecific antibody constructs for cdh3 and cd3

Also Published As

Publication number	Publication date
JPS58166633A (ja)	1983-10-01

Publication	Publication Date	Title
JPH0368507B2 (xx)	1991-10-28
JPH0368506B2 (xx)	1991-10-28
US4405699A (en)	1983-09-20	Manganese dioxide electrode for lithium batteries
CA2173261C (en)	2000-08-08	Lithium-manganese oxide electrode for a rechargeable lithium battery
US4228226A (en)	1980-10-14	Nonaqueous secondary cell using vanadium oxide positive electrode
JPH06342656A (ja)	1994-12-13	電気化学電池およびそのカソード
JP2007516568A (ja)	2007-06-21	改良された陰極を有するリチウム電池
JPS6090827A (ja)	1985-05-22	第一マンガン塩から二酸化マンガンを製造するための過マンガン酸法
JPH07114125B2 (ja)	1995-12-06	非水系二次電池
JPH0251218B2 (xx)	1990-11-06
JPH0251219B2 (xx)	1990-11-06
JPS62186470A (ja)	1987-08-14	非水電解液電池
JPH0316744B2 (xx)	1991-03-06
JPH067483B2 (ja)	1994-01-26	非水電解液電池
JPH0124344B2 (xx)	1989-05-11
JP3017756B2 (ja)	2000-03-13	非水電解液二次電池
JPS62272472A (ja)	1987-11-26	非水溶媒二次電池
JPH0462764A (ja)	1992-02-27	非水電解液電池
JPH0770315B2 (ja)	1995-07-31	非水電解液電池
JP2686072B2 (ja)	1997-12-08	非水電解液電池
JP3021478B2 (ja)	2000-03-15	非水系二次電池
JPH0316745B2 (xx)	1991-03-06
JP2925665B2 (ja)	1999-07-28	非水系電解液電池
JPH0251217B2 (xx)	1990-11-06
JPS6142858A (ja)	1986-03-01	非水電解液電池